Long-Term Debt: Tango Pharma (TNGX)

Investments in Tango Therapeutics (TNGX) carry high uncertainty due to the absence of serial sales and the complexity of passing clinical trials. Funding for current R&D projects relies on existing cash reserves, which are gradually depleting, with the indicator standing at 0.03. This chart reflecting the dynamics of long-term liabilities completes the picture of a business creating targeted drugs whose patent protection will ensure future profitability.

For an investor, analyzing the aggregate multi-year liabilities of Tango Therapeutics (TNGX) is critical when assessing the funding sustainability of robotic high-precision small molecule screening systems. Monitoring the company's current level of long-term debt allows for determining the extent to which oncology drug development depends on borrowed capital and identifying risks of losing credit confidence. This metric measures the total debt load, serving as an indicator of the business's financial security and solvency.